Stromal Keratitis After Varicella in Children.
Anti-Inflammatory Agents
/ administration & dosage
Chickenpox
/ complications
Child
Child, Preschool
Eye Infections, Viral
/ diagnosis
Female
Follow-Up Studies
Herpesvirus 3, Human
Humans
Infant
Keratitis, Herpetic
/ diagnosis
Male
Ophthalmic Solutions
/ administration & dosage
Retrospective Studies
Treatment Outcome
Visual Acuity
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
pubmed:
3
3
2020
medline:
26
3
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
We describe here a case series of patients with stromal keratitis of chronic course, a potential manifestation after chickenpox in children. This is a retrospective review of 8 eyes (7 children) with stromal keratitis after varicella seen in our referral cornea center. All patients received a systemic antiviral treatment with oral acyclovir and topical steroid eye drops. Topical cyclosporine eye drops were associated with steroids in case of steroid dependence or steroid-related side effects. Both antiinflammatory treatments were slowly tapered over time. Median age at diagnosis was 3 years and 4 months. Stromal keratitis was unilateral in 6 children (85.7%) and consisted of superficial nummular keratitis in 4 cases and deep stromal diffuse keratitis in 3 cases. During the median follow-up of 31 months (range, 13-59 months), 6 children had 1 to 6 episodes of relapse. The median duration of topical steroid eye drop was 26 months (range, 2-59 months). Topical cyclosporine eye drops were used with steroids in 3 patients (42.9%). Three patients stopped topical steroids after 2, 5, and 8 months, without recurrence. Four patients were still undergoing treatment after a median of 43 months (range, 26-59 months). All patients regained a best-corrected visual acuity of 20/20 at the end of the follow-up. Stromal keratitis after varicella is an entity with a potential chronic course lasting 3 months or more. Steroid dependence and relapses during tapering are 2 major challenges for the management.
Identifiants
pubmed: 32118671
doi: 10.1097/ICO.0000000000002281
pii: 00003226-202006000-00003
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Ophthalmic Solutions
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
680-684Références
Réseau Sentinelles, INSERM, UPMC. Available at: http://sentiweb.fr. Accessed January 5, 2019.
Kaufman SC. Anterior segment complications of herpes zoster ophthalmicus. Ophthalmology. 2008;115:S24–S32.
Rousseau A, Bourcier T, Colin J, et al. Herpes zoster ophthalmicus—diagnosis and management. US Ophthalmic Rev. 2013;6:1.
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115:S3–S12.
Tran KD, Falcone MM, Choi DS, et al. Epidemiology of herpes zoster ophthalmicus: recurrence and chronicity. Ophthalmology. 2016;123:1469–1475.
Jordan DR, Noel LP, Clarke WN. Ocular involvement in varicella. Clin Pediatr (Phila). 1984;23:434–436.
Ostler HB, Thygeson P. The ocular manifestations of herpes zoster, varicella, infectious mononucleosis, and cytomegalovirus disease. Surv Ophthalmol. 1976;21:148–159.
Griffin WP, Searle CWA. Ocular manifestations of varicella. Lancet. 1953;262:168–169.
Kachmer ML, Annable WL, DiMarco M. Iritis in children with varicella. J Pediatr Ophthalmol Strabismus. 1990;27:221–222.
Wilhelmus KR, Hamill MB, Jones DB. Varicella disciform stromal keratitis. Am J Ophthalmol. 1991;111:575–580.
Frandsen E. Chickenpox in the cornea. Acta Ophthalmol (Copenh). 1950;28:113–120.
Uchida Y, Kaneko M, Hayashi K. Varicella dendritic keratitis. Am J Ophthalmol. 1980;89:259–262.
Nesburn AB, Borit A, Pentelei-Molnar J, et al. Varicella dendritic keratitis. Invest Ophthalmol. 1974;13:764–770.
Littlewood KJ, Ouwens MJNM, Sauboin C, et al. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster. Clin Ther. 2015;37:830–841.e7.
Zhou F. Impact of varicella vaccination on health care utilization. JAMA. 2005;294:797.
Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med. 2005;352:450–458.
Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA. 2002;287:606–611.
Pinot de Moira A, Nardone A; ESEN2 Group. Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2005;10:43–45.
Rentier B, Gershon AA. Consensus: varicella vaccination of healthy children: a challenge for Europe. Pediatr Infect Dis J. 2004;23:379–389.
Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med. 1999;18:3263–3282.